Compass Therapeutics, Inc. (CMPX) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Compass Therapeutics, Inc.
Address
80 Guest Street
Boston, MA 02135
United States of America (the)
Phone
617 500 8099
Sector
Healthcare
Industry
Biotechnology
Employees
35
First IPO Date
April 05, 2021
Key Executives
| Name | Title | Pay | Year Born |
| Thomas J. Schuetz | Chief Executive Officer & Vice Chairman | 1.03M | 1961 |
| Bing Gong | Chief Scientific Officer | 445,500 | 1976 |
| Jonathan Anderman | Senior Vice President, General Counsel & Corporate Secretary | 648,000 | 1983 |
| Barry Shin | Chief Financial Officer | 717,000 | 1972 |
| James Kranz | Vice President and Head of Chemistry Manufacturing & Controls | 0 | N/A |
| Cynthia A. Sirard | Chief Medical Officer | 0 | 1970 |
| Arjun Prasad | Chief Commercial Officer | 0 | 1978 |
| Anna Gifford | Senior Manager of Communications & Chief of Staff | 0 | N/A |
| Neil L. Lerner | Senior Vice President & Chief Accounting Officer | 0 | 1967 |
| Karin Herrera | Senior Vice President & Head of Clinical Operations | 0 | N/A |
Description
Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage programs are CTX-009, an experimental bispecific antibody engineered to inhibit the Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, both of which are crucial for the growth of new blood vessels and tumor vascularization. Another significant compound is CTX-471, an IgG4 monoclonal antibody that functions as an activator of CD137. Furthermore, their developmental pipeline features CTX-8371, a bispecific inhibitor that targets both PD-1 and PD-L1. The company was established in 2014 and operates from its headquarters in Boston, Massachusetts.
